TTrialPathMatch Me to Trials
← Back to trials
RecruitingT-cell LymphomaT-cell Leukemia

CD4CAR for CD4+ Leukemia and Lymphoma

Eligible age

12+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD

Sponsor: Huda Salman

You may qualify if…

  • ✓ In order to be eligible to participate in this study, an individual will be enrolled if they meet the following criteria:
  • ✓ 1. Patients must voluntarily sign and date informed consent forms that state his or her willingness to comply with all study procedures and availability for the duration of the study.
  • ✓ 2. Age 12 years old or older
  • ✓ 3. Subjects with any documented CD4+ T cell hematologic malignancies. Male and female subjects with CD4+ T-cell hematologic malignancies with either relapsed or refractory disease (including those patients who have undergone a prior transplant (if allogeneic, subjects are eligible if there are no remaining donor cells) and patients with an inadequate response after 4-6 cycles of standard chemotherapy) are eligible. Response criteria for each disease subset will be evaluated based on Standard of Care Guidelines.
  • ✓ 4. Creatinine clearance of \> 60 ml/min (or otherwise non clinically-significant, per study investigator)
  • ✓ 5. ALT/AST \< 3 x ULN
  • ✓ 6. Bilirubin \< 2 x ULN
  • ✓ 7. No supplemental oxygen at rest Note: Pulmonary Function Test (PFT) only required per treating physician discretion

You may not qualify if…

  • ✕ 1. Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential (see definition below) must have a negative serum or urine pregnancy test prior to initiation of conditioning chemotherapy, per research sites' clinical policy.
  • ✕ 2. Uncontrolled active infection necessitating systemic therapy.
  • ✕ 3. Active hepatitis B or hepatitis C infection. Active hepatitis C is defined as the hepatitis C antibody is positive while quantitative HCV RNA results exceed the lower detection limit.
  • ✕ Note the following subjects will be eligible:
  • ✕ Subjects with a history of hepatitis B but have received antiviral therapy and have nondetectable viral DNA for 6 months prior to enrollment are eligible
  • ✕ Subjects seropositive for HBS antibodies due to hepatitis B virus vaccine with no signs or active infection (Negative HBs Ag, HBc and HBe Ags) are eligible
  • ✕ Subjects who had hepatitis C but have received antiviral therapy and show no detectable hepatitis C virus (HCV) viral RNA for 6 months are eligible
  • ✕ If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by reverse transcription-polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.

Where it's recruiting

Florida

Miami

Indiana

Indianapolis

New York

New York · Stony Brook

Texas

Houston

Source: ClinicalTrials.gov · NCT03829540 · last updated 2026-06-24